PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
September 24, 2026
September 24, 2026
WASHINGTON, Sept. 24 [Category: BizLaw/Legal] -- WilmerHale, a law firm, posted the following news:
* * *
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
*
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it has completed the previously announced transaction with Sangamo Therapeutics, Inc. to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy product candidate for Fabry disease. The terms include $111 million . . .
* * *
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
*
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it has completed the previously announced transaction with Sangamo Therapeutics, Inc. to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy product candidate for Fabry disease. The terms include $111 million . . .